v3.24.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (5,087,029) $ (6,312,535)
Stock-based compensation expense included in -    
General and administrative costs 773,203 1,502,776
Research and development costs 43,264
Increase (decrease) in -    
Advances on research and development contract services 69,001 3,224
Prepaid insurance 32,108 59,805
Other prepaid expenses 1,350 1,350
Accounts payable and accrued expenses (73,976) 2,318
Research and development contract liabilities (7,922) 88,061
Net cash used in operating activities (4,293,265) (4,611,737)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 3,137,039 5,141,384
Exercise of pre-funded common stock warrants 41
Exercise of common stock options 6,281
Net cash provided by financing activities 3,143,361 5,141,384
Cash:    
Net increase (decrease) (1,149,904) 529,647
Balance at beginning of period 5,353,392 4,823,745
Balance at end of period 4,203,488 5,353,392
Supplemental disclosures of cash flow information:    
Interest 16,233 8,875
Income taxes

Source

HTML PDF
ZIP